



## Biotechnology POOL

### Thomas HOY

Discovery Laboratories Appoints  
Manufacturing VP



Biotechnology company Discovery Laboratories has named Thomas Hoy VP, manufacturing operations. Mr. Hoy is directly responsible for leadership and management of all KL4 surfactant product manufacturing, global supply chain, and pharmaceutical development of Discovery Labs' surfactant replacement therapy products, Surfaxin, Surfaxin LS, and Aerosurf.

Mr. Hoy brings to Discovery Labs experience in product manufacturing, including more than 20 years at Johnson & Johnson, where he most recently served as general manager, global biologics supply chain. He received a pharmacy degree from the Philadelphia College of Pharmacy and Science and an MBA from Drexel University.

### Dr. Aya JAKOBOVITS

New CEO at Kite Pharma



Kite Pharma, a biotechnology company, focused on developing innovative active immunotherapies for cancer, has named Aya Jakobovits, Ph.D., president and CEO. Dr. Jakobovits has more than 20 years of experience in the biotech industry, most recently serving as executive VP, head, research and development at Agensys. She received a Ph.D. in life sciences from the Weizmann Institute of Science in Rehovot, Israel, and was a postdoctoral fellow at Genen-

tech and the University of California, San Francisco.

## Biopharmaceutical POOL

### Richard EISWIRTH

### David HOLLAND

Alimera Sciences Promotes Two  
Executives



Alimera Sciences, a biopharmaceutical company specializing in the research, development, and commercialization of ophthalmic pharmaceuticals, has promoted Chief Financial Officer Richard Eiswirth Jr. to the additional role of chief operating officer.



Alimera also has promoted David Holland, a company co-founder, to senior VP of sales and marketing, from VP of marketing. Mr. Holland manages corporate communications and product sales and marketing, including managed markets, professional and consumer outreach, advertising, and public relations.

### Colin STEWART

Amarin Names New CEO



Amarin, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, has appointed Colin Stewart president and CEO. Mr. Stewart is responsible for driving forward the company's strategy to maximize the value of its lead product, AMR101, a new drug

being studied for the treatment of high triglycerides. Mr. Stewart has more than 30 years of experience in executive management and commercial positions for pharmaceutical companies, including five years as president and CEO of CollaGenex Pharmaceuticals.

## Specialty POOL

### Daniel WECHSLER

Former Merck Executive Heads Up  
Bausch + Lomb Pharma Business



Global eye-health company Bausch + Lomb has named Daniel Wechsler corporate VP and global president of its pharmaceuticals business. Mr. Wechsler was most recently head of U.S. strategy, commercial model innovation, and business development for Merck.

## Agency POOL

### Nicholas CAPANEAR

### Kathleen FINNERTY

### Beth GATES

### Patty GATES

### David HYMSON

### Megan MALLIE

### Andrew MCGUIRE

### Cathy MIDURA

### Onix RAMOS

### Glenn THORPE

### Danielle TYBURSKI

### Dana VALENTI

### Russ WAKELIN

### Benjamin WILLIS

Sudler & Hennessey Announces Additions,  
Promotions

Sudler & Hennessey (S&H), a full-service

global healthcare marketing and communications organization, has made a number of additions and promotions to its staff.

Nicholas Capanear has joined S&H's Senatrix Health Communications division as senior VP, creative director.

Kathleen Finnerty has joined the S&H San Francisco staff as VP, account services. Ms. Finnerty's previous experience includes CRM strategist and account director at DDB.

Beth Gates has been promoted to VP, senior program director with S&H's Precept Medical Communications division. Patty Gates has been promoted to VP, editorial services.



David Hymson has been named senior VP, senior strategic planner. Mr. Hymson's previous experience spans a range of account service and strategic roles.



Megan Mallie has been promoted to creative director, brand development.



Andrew McGuire has been appointed senior VP, media director. Mr. McGuire joins S&H from Elsevier.



Cathy Midura has advanced to senior VP, management supervisor.



Onix Ramos has been promoted to VP, operations.




Glenn Thorpe has been promoted to VP, senior program director for S&H's Precept Medical Communications division.



S&H has named Danielle Tyburski VP, account group supervisor for S&H Digital. Ms. Tyburski's recent experience includes overseeing accounts at Universal Buzz.



Dana Valenti has been promoted to senior VP, IntraMed Speakers Bureau.



Russ Wakelin has been elevated to VP, associate creative director.



Benjamin Willis has joined S&H as senior VP, account management. Mr. Willis's previous experience includes stints at Harrison & Star, DDB, and Lyonheart.

## Barry LEVINE

New Creative Director at AbelsonTaylor

Independent healthcare advertising agency AbelsonTaylor has promoted Barry Levine to



creative director. Mr. Levine has been with AbelsonTaylor since 1998, most recently serving as associate creative director.

Mr. Levine received an M.S. in advertising with a concentration in creative strategy and execution from Northwestern University.

## Abby MANSFIELD

Topin Promotes Creative Lead



Full-service healthcare advertising agency Topin & Associates has promoted Abby Mansfield to senior VP, creative director, responsible for leading all aspects of the agency's creative depart-

ment.

Ms. Mansfield has been with Topin for almost 15 years.

## Michael PARISI

Ogilvy CommonHealth Promotes Altum President to Managing Partner



Ogilvy CommonHealth Worldwide, a WPP healthcare communications company, has tapped Michael Parisi to serve as a managing partner.

Mr. Parisi is responsible for co-leading the Ogilvy CommonHealth network and overseeing the group's New York office and specialty marketing agency.

Mr. Parisi was previously founder and president of Altum, CommonHealth's full-service advertising and promotion agency focused on high-science and specialty markets.

## Brian PETERS

MedThink Appoints Group Account Director



Brian Peters has joined full-service healthcare communications company MedThink Communications as group account director.

Mr. Peters' responsibilities include integrating and managing promotional advertising and medical communications for MedThink's portfolio of United Therapeutics business, which includes treatments for pulmonary arterial hypertension (PAH).

### STATEMENT OF OWNERSHIP, MANAGEMENT, AND CIRCULATION

1. Publication title: PharmaVOICE
2. Publication no.: #23626
3. Filing date: September 30, 2010
4. Issue frequency: published monthly except combined issues in July/August and Nov./Dec.
5. No. of issues published annually: 10
6. Annual subscription price: US: \$190. Non-US: \$360.
7. Complete mailing address of known office of publication: PharmaLinx LLC, 244 Jacobs Creek Road, Titusville, NJ 08560, Titusville, NJ 08560
8. Complete mailing address of headquarters or general business office of publisher: PharmaLinx LLC, 244 Jacobs Creek Road, Titusville, NJ 08560, Titusville, NJ 08560
9. Full names and complete mailing addresses of publisher, editor, and managing editor: Lisa Banket, P.O. Box 327, Titusville, NJ 08560, Taren Grom, P.O. Box 327, Titusville, NJ 08560, and Denise Myshko, P.O. Box 327, Titusville, NJ 08560
10. Owner: Lisa Banket, Taren Grom, and Marah Walsh
11. Known bondholders, mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities: (none)
13. Publication title: PharmaVOICE
14. Issue date for circulation data below: September 2010
15. Extent and nature of circulation (avg. no. copies each issue during preceeding 12 months and actual no. copies of single issue published nearest to filing date, respectively). Total no. copies - 18,130 and 18,000. Individual paid/requested mail subscriptions stated on Form 3541: 15,960 and 15,597. Sales through dealers and carriers, street vendors, counter sales, and other paid or requested distribution outside USPS: 34 and 9. Total paid and/or requested circulation: 15,994 and 15,606. Nonrequested copies stated on Form 3541: 1,687 and 1,959. Nonrequested copies distributed outside the mail: 123 and . Total nonrequested distribution: 1,810 and 2,034. Total distribution: 17,804 and 17,640. Copies not distributed: 326 and 360. Total: 18,130 and 18,000. Percent paid and/or requested circulation: 89.83 and 88.47.
16. This statement of ownership will be printed in the November/December 2010 issue of this publication.
17. I certify that all information furnished on this form is true and complete. I understand that anyone who furnishes false or misleading information on this form or who omits material or information on the form may be subject to criminal sanctions (including fines and imprisonment) and/or civil sanctions (including civil penalties). (Signed) Marah Walsh, Founding Partner

He has more than 20 years of experience in biotech and pharma marketing, most recently as senior director, marketing, for Accera.

**Renée WILLS**

ICC Trio Hires General Manager



Renée Wills has joined full-service pharmaceutical communications agency ICC Trio as general manager.

Ms. Wills has more than 18 years of healthcare marketing experience, with solid expertise in diverse therapeutic categories on both the client and agency sides.

**CRO POOL**

**Garry JOHNSON**

BioClinica Creates Technology Chief Role



BioClinica, a global provider of clinical trial management services, has appointed Garry Johnson senior VP and chief technology officer.

Mr. Johnson leads the company's global technology strategy, developing and implementing BioClinica's technology plan.

Mr. Johnson has more than 15 years of experience leading international technology organizations through the strategic development and execution of business-aligned IT plans. He most recently served as senior VP and global chief technology officer for Cegedim.

**Dr. Anthony MAIDA**

PharmaNet Names Head of Oncology Team



PharmaNet Development Group, a provider of drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries, has appointed Anthony

Maida, Ph.D., VP, clinical research, responsible for leading PharmaNet's oncology team. Dr. Maida has more than 20 years of experience providing strategic, operational, and financial expertise to pharma companies focused primarily in the area of oncology. Most recently, he ran his own consulting firm.

He received an MBA from the University of Santa Clara, a master's degree in toxicology from San Jose State University, and a Ph.D. in tumor immunology from the University of California, Davis.

**Dr. Neil MCCULLOUGH**

PPD Names Quality Management VP



Global contract research organization PPD has appointed Neil McCullough, Ph.D., VP of quality management systems. Dr. McCullough is responsible for providing strategic direction for quality management across all lines of business and ensuring full compliance with global regulations guiding the biopharmaceutical industry.

Dr. McCullough joins PPD after nine years at Pfizer, where he most recently served as senior director of the global research and development division good clinical practice and good laboratory practice quality assurance leadership team. He received a doctorate in chemistry from The University of Kent at Canterbury in the United Kingdom.

**Dr. Mark ROSEMAN**

**Jeffrey ZUCKER**

Kendle Adds to Marketing, Patient Recruitment Teams



Global full-service clinical research organization Kendle has appointed Mark Roseman, D.Sc., senior VP and chief marketing officer, responsible for the company's worldwide sales and strategic partnership development efforts. Dr. Roseman joins Kendle from i3 Research, where he was most recently VP, business operations. He holds a doctor of science in epidemiology and a master of public health in biostatistics and epidemiology, both from Boston University School of Public Health; and a doctor of optometry and a master of science in physiological optics, both from The Ohio State University College of Optometry.



Jeffrey Zucker has joined Kendle as senior director and global head, patient recruitment, providing global leadership for the development and implementation of strategies to accelerate patient recruitment, improve retention, and support the timely and efficient delivery of Phase I to Phase IV clinical development programs.

Mr. Zucker most recently led global trial optimization efforts at Merck. He received a

master of science in group process and group psychotherapy from Hahnemann University.

**Dr. C. Jo WHITE**

INC Research Appoints Infectious Disease Specialist



INC Research, a therapeutically focused CRO, has appointed C. Jo White, M.D., VP, clinical development of infectious diseases.

Dr. White has 23 years of experience in the pharmaceutical industry with a focus in vaccine development. Dr. White holds an M.D. from Baylor College of Medicine with Alpha Omega Alpha honors and is board-certified in both internal medicine and infectious diseases.

**Service POOL**

**Dr. Peter CHERRY**

**Kevin FARBEROW**

**Jodi MALCOM**

MedMeme Adds Three VPs

MedMeme, a provider of key opinion leader data and competitive intelligence, has made three additions to its executive team.

Peter Cherry, Ph.D., has been appointed VP of information systems. Dr. Cherry is responsible for overseeing the data integration and analysis functions of the company in the wake of its acquisition of Medical Intelligence Solutions, Dr. Cherry's former company.

Kevin Farberow has assumed the role of senior VP, global sales and marketing, with responsibility for overall sales and marketing activities. He previously served as VP of sales and marketing at MIS.

Jodi Malcom has joined MedMeme as VP of sales, with responsibility for domestic sales of several of MedMeme's service lines. Ms. Malcom was most recently a partner at Sherburne Medical Media. ♦



Send your personnel announcements to [feedback@pharmavoice.com](mailto:feedback@pharmavoice.com).

SEE DIGITAL EDITION FOR BONUS CONTENT  
[WWW.PHARMAVOICE.COM](http://WWW.PHARMAVOICE.COM)

Join us for the *20<sup>th</sup> Anniversary Celebration*



March 30 - April 1, 2011  
Phoenix Convention Center • Phoenix, AZ



WHAT'S IN STORE FOR PARTNERSHIPS 2011

# ALL STAR SPEAKER LINE-UP

THOMAS GOETZ, MPH		Executive Editor, <b>WIRED MAGAZINE</b> , Author, <i>The Decision Tree</i>
DAN HEATH		Best-selling author of "Switch - How To Change Things When Change Is Hard" and "Made-To-Stick"
GUY ADAMI		CNBC " <b>Fast Money</b> " Contributor & Managing Director, <b>Drakon Capital</b>
VIJAY GOVINDARAJAN		Founding Director of the Global Leadership at the Tuck School of Business, <b>Dartmouth College</b> , Co-author, " <b>The Other Side of Innovation: Solving the Execution Challenge</b> "
CURT SCHILLING		Former Major League Baseball Pitcher and 3 Time World Series Champion, Founder and Chairman, <b>38 Studios</b> and Founder, <b>Curt's Pitch for ALS</b>

# NEW CONTENT & INSIGHTS

- An all-star line-up of **200+ speakers** representing the top national and global pharma biotech innovators
- Delve deeper into **NEW focus areas** including emerging markets, e-clinical technologies, quality oversight and much more
- All-access pass to 3 new targeted events for **investigator and site management professionals**, **medical device professionals** and **Pharma and biotech investors**
- Partnerships **Hall of Fame Awards** honor Partnerships MVPs over the last 20 years
- **5 all new tracks** to give you the latest **SCORE!**
  - :: **S**trategic Sourcing and Alliances
  - :: **C**ontract and Budget Management
  - :: **O**perations Excellence
  - :: **R**egulatory Compliance and Quality Oversight
  - :: **E**-clinical Technologies

# THANK YOU TO OUR PARTNERS

Marquee Sponsor

Platinum Sponsors



Gold Sponsors



Associate Sponsors



Supporting Sponsors



Official Media Partner



Mention your VIP Code XP1600PHVCNOV for up to \$800 in Savings when Registering!

Visit [www.clinicaltrialpartnerships.com](http://www.clinicaltrialpartnerships.com)

## TALENT pool

Biopharmaceutical **POOL**Michael **BAILEY**Dr. Donna **RADZIK**

## Aveo Pharmaceuticals Bolsters Leadership

Aveo Pharmaceuticals, a biopharmaceutical company focused on discovering, developing, and commercializing cancer therapeutics, has appointed Michael Bailey chief commercial officer. Mr. Bailey joins Aveo from Synta Pharmaceuticals, where he served as senior VP, business development and chief commercial officer.

He received an MBA in international marketing from the Mendoza College of Business, University of Notre Dame.

Donna Radzik, Ph.D., has joined Aveo as VP, technical operations. Dr. Radzik was previously VP, technical operations at Sanofi Pasteur Biologics. She earned a Ph.D. in analytical chemistry from Purdue University.

Marc **BEER**

## Aegerion Names CEO

Aegerion Pharmaceuticals, a privately held biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, has named Marc Beer CEO.

Mr. Beer has more than 20 years of experience in biotechnology, pharmaceuticals, and diagnostics, most recently as the founding CEO of ViaCell, which was acquired by PerkinElmer in 2007.

Dr. Werner **CAUTREELS**

## Former Solvay CEO Takes Helm at Selecta Biosciences

Selecta Biosciences, a biopharmaceutical company developing synthetic nanoparticle vaccines and immunotherapies, has named Werner Cautreels, Ph.D., president and CEO. Dr. Cautreels has more than 25 years of experience as a pharmaceutical executive and R&D leader, most recently as CEO for Solvay Pharmaceuticals, which was acquired by Abbott Laboratories earlier this year.

He received a doctorate in chemistry from the University of Antwerp in Belgium.

Dr. Giora **FEUERSTEIN**

## Intellect Neurosciences Taps Former Pfizer VP as Consultant

Intellect Neurosciences, a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and other disorders, has engaged Giora Feuerstein, M.D., as a key consultant advising the company on its technology programs and pipeline.

Until earlier this year, Dr. Feuerstein was assistant VP and head, discovery translational medicine, at Pfizer.

Debanjan **RAY**

## Itero Biopharmaceuticals Promotes VP

Itero Biopharmaceuticals has promoted Debanjan Ray to VP, business development, responsible for leading business development efforts aimed at expanding the biopharmaceutical company's pipeline of differentiated protein therapeutics. Mr. Ray joined Itero in 2008 as director, commercial development. Mr. Ray holds an MBA from The Wharton School, University of Pennsylvania.

pump unwanted or toxic substances away from vulnerable tissues, has named Jill Carroll VP of strategic corporate development.

Ms. Carroll comes from Dynavax Technologies, where she was responsible for corporate development and strategic planning. She received an M.S. in biochemistry, cellular, and molecular biology from Johns Hopkins University.

Robert **SAVEL**

## Inspire Appoints Head of Manufacturing, Technical Operations

Inspire Pharmaceuticals, a biopharmaceutical company focused on researching, developing, and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases, has appointed Robert Savel senior VP and chief technical officer, with responsibility for all manufacturing and technical operations.

Mr. Savel has extensive experience in operations, quality, and supply chain management in both commercial and research and development areas. Most recently, he served as president of Savel Enterprises.

Discovery **POOL**Dr. Leslie **MOLONY**Dr. Carl **WARE**

## Sanford-Burnham Adds Two Directors

Leslie Molony, Ph.D. has joined Sanford-Burnham Medical Research Institute as senior director, business development. Dr. Molony is leading Sanford-Burnham's activities to develop and implement strategies for establishing new collaborations and licensing technology based on research coming out of the institute. Dr. Molony was most recently president and CEO of Transgeneron Therapeutics. She received a Ph.D. in anatomy/cell biology from Duke University and completed postdoctoral studies at the University of North Carolina.

In other moves, Carl Ware, Ph.D., has been appointed director of the Infectious and Inflammatory Disease Center (IIDC) at Sanford-Burnham, overseeing the institute's work on HIV, influenza, anthrax, rheumatoid arthritis, Crohn's disease, and autoimmune disorders. Dr. Ware previously headed the division of molecular immunology at the La Jolla Institute for Allergy & Immunology. He earned a Ph.D. in molecular biology and biochemistry at the University of California, Irvine, and conducted postdoctoral research at UC Irvine, the University of Texas, and the Dana Farber Cancer Institute.

Genomics **POOL**Dr. Norrie **RUSSELL**

## Gene Logic Appoints President

Gene Logic, an Ocimum Biosolutions company and provider of genomic solutions, has named Norrie Russell, Ph.D., president. Dr. Russell has held leadership roles with NovaRx, Invitrogen, Aviva Biosciences, and Lynx Therapeutics.

Specialty **POOL**Dr. Declan **DOOGAN**

## Prometheus Names Medical Chief

Prometheus Laboratories, a specialty phar-

maceutical and diagnostic company, has appointed Declan Doogan, M.D., executive VP and chief medical officer. Dr. Doogan has more than three decades of drug development experience and most recently served as interim CEO and head of research and development for Amarin. He received a medical degree from Glasgow University in Scotland and is a fellow of the Royal College of Physicians of Glasgow and the Faculty of Pharmaceutical Medicine in the United Kingdom.

---

## Drug-Delivery **POOL**

---

### Benny **WARD**

BioDelivery Sciences Hires Strategic Development Head

BioDelivery Sciences International (BDSI), a specialty pharmaceutical company leveraging its patented drug delivery technologies to develop and commercialize new applications of proven therapeutics, has appointed Benny Ward as executive VP of business and strategic development. Mr. Ward is responsible for leading BDSI's business and strategic development initiatives and investor relations activities. He was previously VP of finance and chief financial officer of Closure Medical Corporation.

---

## Device/Diagnostic **POOL**

---

### Dr. Herbert **FRITSCHÉ**

Former MD Anderson Cancer Professor Joins Health Discovery Corporation

Health Discovery Corporation, a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable, has appointed Herbert Fritsche, Ph.D., senior VP and chief science officer.

Dr. Fritsche recently retired as professor of laboratory medicine and chief of the clinical chemistry section at the University of Texas MD Anderson Cancer Center. In his 41 years at MD Anderson, Dr. Fritsche focused his research activities on the development and validation of cancer diagnostics, and he has been involved with the commercialization of every serum cancer biomarker product in use in the United States, as well as many of the new tissue-based molecular markers.

### Dr. Christopher

### **PRITCHARD**

InVivo Therapeutics Promotes Science Chief

InVivo Therapeutics, a medical device company focused on combining polymers and stem cells to restore function in individuals paralyzed as a result of traumatic spinal cord injury, has promoted Christopher Pritchard, Ph.D., to chief science officer from director of research & development.

Dr. Pritchard holds a Ph.D. from the Massachusetts Institute of Technology.

---

## Emerging **POOL**

---

### Nick **LESCHLY**

bluebird bio Selects Chief Executive

bluebird bio, a developer of innovative gene therapies for severe genetic disorders formerly known as Genetix Pharmaceuticals, has appointed Nick Leschly president and CEO.

Mr. Leschly has been a partner of Third Rock Ventures since its founding in 2007 and became interim president of bluebird bio in March 2010 in conjunction with Third Rock's investment in the company.

He has an MBA from The Wharton School, University of Pennsylvania and is founder and chairman of the CAVU Foundation, a non-profit dedicated to improving the health of underprivileged children.

---

## Consulting **POOL**

---

### Ari **BOUSBIB**

New CEO Takes Helm at IMS Health

IMS Health, a global provider of market intelligence to the pharmaceutical and healthcare industries, has named Ari Bousbib CEO.

The change is part of a planned succession in which former CEO David Carlucci continues to serve as chairman of IMS Health for a transition period.

Mr. Bousbib joins IMS after a 14-year career with United Technologies Corporation (UTC), where he served in several senior leadership positions, most recently as president of UTC's Commercial Companies — Otis Eleva-

tor Company, Carrier Corporation, and UTC Fire & Security.

### Simona **CIPRA**

### Bradley **YOUNT**

HCG Enhances Management Team

Halloran Consulting Group (HCG), a management consulting firm delivering clinical development strategies and services for emerging and established life-sciences companies, has expanded its leadership roster.

Simona Cipra has joined HCG as a managing director. Ms. Cipra was previously VP of global clinical operations for a midsized, oncology-focused biopharmaceutical company.

Bradley Yount, founder and president of Odyssey Bay Ventures, has been named chief operating officer.

### Dr. Sidney **MAZEL**

PRTM Names Transaction Services VP

Sidney Mazel, Ph.D. has joined global management consulting firm PRTM as executive VP of transaction services for the health-care business group.

Dr. Mazel has almost 20 years of experience within the biopharmaceutical industry, most recently serving as senior VP of product planning and portfolio management at MedImmune.

He received an M.A. from George Washington University and a Ph.D. in exercise physiology from the University of Maryland.

---

## CRO **POOL**

---

### Evelyn **GRAHAM**

Worldwide Clinical Trials Appoints VP

Worldwide Clinical Trials, a privately held global contract research organization, has named Evelyn Graham executive VP, global business development, leading sales, marketing, and business development strategies for the company's late-stage business.

Ms. Graham was previously CEO of TorreyPines Therapeutics. She received an MBA from the University of Connecticut.

## TALENT pool

Dr. Eve **MYLCHREEST**

Former Pfizer Scientist Joins Southern Research Institute

Nonprofit research organization Southern Research Institute has named Eve Mylchreest, Ph.D., to lead its reproductive toxicology group.

Dr. Mylchreest was previously a principal research scientist in reproductive toxicology for Pfizer. She received masters and doctorate degrees in toxicology from the Université de Montréal in Canada.

Patrick **WALSH**

Pharma Manufacturing Veteran Joins AAIPharma as CEO

AAIPharma Services, a provider of pharmaceutical product development services, has named Patrick Walsh CEO.

Mr. Walsh is focused on advancing AAIPharma's next phase of strategic growth following its establishment as a stand-alone company.

With almost 30 years of pharmaceutical manufacturing experience, Mr. Walsh has served in executive roles at multiple pharmaceutical companies, including as president and CEO of Kadmus Pharmaceuticals and president and chief operating officer of Gensia Sico.

Most recently, he founded a management consulting firm that assisted companies with achieving key corporate objectives in the phar-

maceutical, contract manufacturing, and biotechnology industries.

Technology **POOL**Jim **HYDE**Adam **SLOVIK**

Leadership Shifts at RemedyMD

Jim Hyde has joined RemedyMD, a provider of registries for life sciences, as president and chief operating officer. Mr. Hyde's previous experience includes stints as chief operating officer for In-Store Broadcasting Network and Overstock.com, and VP of applications development at Tenfold.

He received a master's degree from MIT and a Ph.D. in mechanical engineering from Stanford University.

Mr. Hyde succeeds Adam Slovik, who has assumed the role of chief technology officer at RemedyMD, focused on the development of resalable registries and tools.

Jerry **SCHORN**

iMany Appoints Global Sales VP

Contract performance solutions provider iMany has appointed Jerry Schorn VP of glob-

al sales, with responsibility for leading the sales organization and providing strategic direction to iMany's sales operations.

Mr. Schorn also plays a leading role in managing and expanding iMany's customer accounts as part of the company's growth objectives.

He was most recently North America sales leader at IBM.

Dr. Bonnie **TESCHENDORF**

CRF Health Strengthens Outcomes Expertise

CRF Health, a provider of ePRO (electronic patient reported outcomes) solutions for the life-sciences industry, has named Bonnie Teschendorf, Ph.D., patient reported outcomes scientific advisor.

Dr. Teschendorf leads the company's PRO consulting initiative, providing scientific insight and guidance to CRF Health clients and internal staff, as well as to the global clinical trial sector.

Dr. Teschendorf was previously director of patient reported outcomes at Johnson & Johnson. She received a doctorate from the Mailman School of Public Health at Columbia University and a master of health services administration from the New School for Social Research. ♦

Send your personnel announcements to [feedback@pharmavoice.com](mailto:feedback@pharmavoice.com).

**MORE Options.**  
**MORE Opportunities.**  
**MORE Results.**



**QUALIFIED LEADS**  
Recent Event Statistics  
850+ registrants  
400+ attendees  
**MEASURABLE RESULTS**

**The Next Generation  
of Publication Marketing**

## **The PharmaVOICE WebLinx Program**

PHARMAVOICE MODERATED • EDUCATION RICH • LIVE • INTERACTIVE • SPONSOR HOSTED

Accelerate your marketing campaign with a program designed to generate **qualified leads** and **measurable results**.

- Customize to your target audience — establish your expertise
- Leverage the PharmaVOICE brand to deliver interested participants — generate qualified leads
- Capitalize on pre- and post-seminar pull-through — build sustainable interest
- Use an experienced provider with proven results

For more information about WebLinx Programs, call 609-730-0196 to speak with Lisa Banket, Publisher (lbanket@pharmavoices.com), or contact Marah Walsh, New Business Development 215-321-8656 (mwalsh@pharmavoices.com)

**Read. Think. Participate.**

[www.pharmavoices.com/weblinx](http://www.pharmavoices.com/weblinx)